Literature DB >> 23850695

Application of real-time RT-PCR in vector surveillance and assessment of replication kinetics of an emerging novel ECSA genotype of Chikungunya virus in Aedes aegypti.

Ankita Agarwal1, Anil K Singh, Shashi Sharma, Manisha Soni, Ashish K Thakur, N Gopalan, M M Parida, P V L Rao, Paban K Dash.   

Abstract

Chikungunya has emerged as one of the most important arboviral infection of global significance. Expansion of Chikungunya virus endemic areas can be ascribed to naive population, increasing vector population and adaptability of virus to new vector. In this study, a SYBR Green I based quantitative RT-PCR assay was developed. The assay was found to be 10-fold more sensitive than conventional RT-PCR and no cross reactivity was observed with related alphaviruses and flaviviruses. The detection efficiency of the assay was impervious to mosquitoes of different pool sizes. Vector surveillance has resulted in detection of CHIKV RNA in Aedes aegypti, confirming its vectorial potential for CHIKV in northern India. The assessment of the assay was further carried out by studying the competence of Indian Ae. aegypti for CHIKV, which revealed 100% infection rate and dissemination rate with 60% transmission rate. The replication kinetics of CHIKV in different anatomical sites of Ae. aegypti revealed highest titre at day 6 post infection in midgut and at day 10 post infection in saliva, legs and wings. The implementation of the assay in detecting lower viral load makes it a remarkable tool for surveillance of virus activity in mosquitoes.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aedes aegypti; Chikungunya; Dissemination; RT-PCR; Transmission; Vector surveillance

Mesh:

Year:  2013        PMID: 23850695     DOI: 10.1016/j.jviromet.2013.07.004

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Selective Estrogen Receptor Modulators Limit Alphavirus Infection by Targeting the Viral Capping Enzyme nsP1.

Authors:  Rajat Mudgal; Chandrima Bharadwaj; Aakriti Dubey; Shweta Choudhary; Perumal Nagarajan; Megha Aggarwal; Yashika Ratra; Soumen Basak; Shailly Tomar
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.938

2.  Molecular and virological investigation of a focal chikungunya outbreak in northern India.

Authors:  Manisha Soni; Anil Kumar Singh; Shashi Sharma; Ankita Agarwal; Natarajan Gopalan; P V Lakshmana Rao; Manmohan Parida; Paban Kumar Dash
Journal:  ScientificWorldJournal       Date:  2013-12-24

3.  Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.

Authors:  Shweta Saraswat; T N Athmaram; Manmohan Parida; Ankita Agarwal; Amrita Saha; Paban Kumar Dash
Journal:  PLoS Negl Trop Dis       Date:  2016-07-11

4.  Development of a SYBR green I-based quantitative RT-PCR for Ross River virus: Application in vector competence studies and antiviral drug evaluation.

Authors:  Paban Kumar Dash; Ankita Agarwal; Shashi Sharma; Amrita Saha; Gaurav Joshi; Natarajan Gopalan; Devanathan Sukumaran; Man Mohan Parida
Journal:  J Virol Methods       Date:  2016-04-19       Impact factor: 2.014

5.  Evidence of experimental vertical transmission of emerging novel ECSA genotype of Chikungunya Virus in Aedes aegypti.

Authors:  Ankita Agarwal; Paban Kumar Dash; Anil Kumar Singh; Shashi Sharma; Natarajan Gopalan; Putcha Venkata Lakshmana Rao; Man Mohan Parida; Paul Reiter
Journal:  PLoS Negl Trop Dis       Date:  2014-07-31

6.  Virus load and clinical features during the acute phase of Chikungunya infection in children.

Authors:  Siva Raghavendhar B; Ashok Kumar Patel; Sushil Kumar Kabra; Rakesh Lodha; Vinod H Ratageri; Pratima Ray
Journal:  PLoS One       Date:  2019-02-01       Impact factor: 3.240

7.  Vector-delivered artificial miRNA effectively inhibited replication of Chikungunya virus.

Authors:  Amrita Saha; Sameer S Bhagyawant; Manmohan Parida; Paban Kumar Dash
Journal:  Antiviral Res       Date:  2016-08-23       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.